Iovance Biotherapeutics, Inc. (0JDK.L) LSE
4.11
+0.092(+2.29%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Iovance Biotherapeutics, Inc.
Address
825 Industrial Road
San Carlos, CA 94070
United States of America (the)
Phone
650 260 7120
Website
Sector
Healthcare
Industry
Biotechnology
Employees
838
First IPO Date
January 29, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Frederick G. Vogt | Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director | 1.13M | 1974 |
| Elma S. Hawkins | Advisor to the Board | 465,395 | 1957 |
| Corleen Roche | Chief Financial Officer | 494,150 | 1966 |
| Igor Bilinsky | Chief Operating Officer | 738,374 | 1973 |
| Friedrich Graf Finckenstein | Chief Medical Officer | 764,634 | 1967 |
| Daniel G. Kirby | Chief Commercial Officer | 804,031 | 1972 |
| Raj K. Puri | Chief Regulatory Officer | 867,158 | 1956 |
| Sara Pellegrino | Senior Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Tracy Winton | Executive Vice President of Human Resources | 0 | N/A |
| Marc R. Theoret | Senior Vice President of Regulatory Strategy | 0 | N/A |
| Brian Shew | Senior Vice President & Head of Digital and Information Technology | 0 | N/A |
| Matthew W. Rosinack | Principal Accounting Officer | 0 | 1972 |
| Howard Johnson | Chief Business Officer | 0 | 1960 |
| Kevin Smyth | Executive Vice President of Quality | 0 | N/A |
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
